Dataset from Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)

Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study
doctors think that giving medicines to affect the immune system soon after diabetes is
diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better
glucose control.

Researchers believe that tocilizumab could have some effect on the cells in the immune system
that are thought to be involved in the development of type 1 diabetes. This study will test
whether tocilizumab can help preserve or delay destruction of remaining beta cells in people
recently diagnosed type 1 diabetes.

1型糖尿病（Type 1 diabetes mellitus, T1DM）是一种自身免疫性疾病。基于既往研究成果，本研究的医师团队认为，在糖尿病确诊后尽早使用调控免疫系统的药物，或可阻止、延缓或减轻β细胞的破坏，进而实现更优的血糖控制效果。
研究人员推测，托珠单抗（tocilizumab）可对参与1型糖尿病发病进程的免疫细胞发挥一定作用。本研究将评估托珠单抗是否能够帮助保留或延缓新近确诊1型糖尿病患者体内剩余β细胞的破坏进程。